Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity

American Journal of Obstetrics and Gynecology

Volumn 200, Issue 2, 2009, Pages 180.e1-180.e7

  Bull Phelps, Shawna L ^a   Carbon, Juliet ^b   Miller, Andrew ^b   Castro Rivera, Emely ^b   Arnold, Shanna ^b   Brekken, Rolf A ^a,b   Lea, Jayanthi S ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Hamon Center for Therapeutic Oncology Research   (United States)

Author keywords

Chemosensitivity; extracellular matrix; murine; ovarian cancer; secreted protein acidic and rich in cysteine

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; MAB 303; OSTEONECTIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CHEMOSENSITIZATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 58749096351     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.08.047     Document Type: Article

References (22)

1. Brekken R.A., Puolakkainen P., Graves D.C., Workman G., Lubkin S.R., and Sage E.H. Enhanced growth of tumors in SPARC-null mice is associated with changes in the ECM. J Clin Invest 111 (2003) 487-495
2. Yiu G.K., Chan W.Y., Ng S.W., et al. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 159 (2001) 609-622
3. Said N., and Motamed K. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol 167 (2005) 1739-1752
4. Framson P.E., and Sage E.H. SPARC and tumor growth: where the seed meets the soil?. J Cell Biochem 92 (2004) 679-690
5. Sato N., Fukushima N., Maehara N., et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 22 (2003) 5021-5030
6. Koukourakis M.I., Giatromanolaki A., Brekken R.A., et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 63 (2003) 5376-5380
7. Brown T.J., Shaw P.A., Karp X., Huynh M.H., Begley H., and Ringuette M.J. Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecol Oncol 75 (1999) 25-33
8. Paley P.J., Goff B.A., Gown A.M., Greer B.E., and Sage E.H. Alterations in SPARC and VEGF Immunoreactivity in epithelial ovarian cancer. Gynecol Oncol 78 (2000) 336-341
9. Mok S.C., Chan W.Y., Wong K.K., Muto M.G., and Berkowitz R.S. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene 12 (1996) 1895-1901
10. Tai I.T., Dai M., Owen D.A., and Chen L.B. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest 115 (2005) 1492-1502
11. Markman M. The myth of measurable disease in ovarian cancer. J Clin Oncol 21 (2003) 3013-3015
12. Brewer C.A., Blessing J.A., Nagourney R.A., Morgan M., and Hanjani P. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 103 (2006) 446-450
13. Mutch D.G., Orlando M., Goss T., et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25 (2007) 2811-2818
14. Roby K.F., Taylor C.C., Sweetwood J.P., et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21 (2000) 585-591
15. Sweetwyne M.T., Brekken R.A., Workman G., et al. Functional analysis of the matricellular protein SPARC with novel monoclonal antibodies. J Histochem Cytochem 52 (2004) 723-733
16. Shi Q., Bao S., Maxwell J.A., Reese E.D., et al. Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J Biol Chem 279 (2004) 52200-52209
17. Lea J.S., Ashfaq R., Muneer S., et al. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development. J Soc Gynecol Investig 11 (2004) 329-337
18. Norose K., Clark J.I., Syed N.A., et al. SPARC deficiency leads to early-onset cataractogenesis. Invest Ophthalmol Vis Sci 39 (1998) 2674-2680
19. Ledda M.F., Adris S., Bravo A.I., et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 3 (1997) 171-176
20. Sangaletti S., Stoppacciaro A., Guiducci C., Torrisi M.R., and Colombo M.P. Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. J Exp Med 198 (2003) 1475-1485
21. Perez R.P. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34 (1998) 1535-1542
22. Hoskins W.J., Perez C.A., Young R.C., Barakat R.B., Markman M., and Randall M.E. Principles and practice of gynecologic oncology. 4th ed. (2005), Lippincott Williams & Wilkins, Philadelphia 468-471